Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)
Authors
Lorenzo Antonuzzo (ORCID: https://orcid.org/0000-0003-3349-5604)
Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)
Lorenzo Antonuzzo, Nicola Normanno, Saverio Cinieri, Concetta Di Micco et al.
Journal
BMC Cancer
Topics
Lung Cancer Research Studies
article
Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)
Lorenzo Antonuzzo, Nicola Normanno, Saverio Cinieri, Concetta Di Micco, Angela Damato, Rossana Berardi, F Grossi, Carmine Pinto, Sara Pusceddu, Angela Buonadonna, Francesca Spada, Giuseppe Maglietta, Fabio Gelsomino, S. Cesario, Nicole Brighi, Erika Gervasi, Francesco Iachetta, Giamaica Ciardiello, Erika Martinelli
article en
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
University of Insubria (IT), University of Modena and Reggio Emilia (IT), Marche Polytechnic University (IT), University of Parma (IT), University of Campania "Luigi Vanvitelli" (IT), Casa Sollievo della Sofferenza (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale A. Perrino (IT), Centro di Riferimento Oncologico (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), European Institute of Oncology (IT)